Poor
Not Aligned
Patient Risk:
Moderate
Summary
The AI response does not directly evaluate the specific Cosentyx–MMR/vaccine-efficacy claims provided. Instead, it asserts a generalized safety/risks mapping without evidence tied to each claim; therefore most claims are effectively unsupported or unassessed against the provided FDA label excerpts.
Category Scores
Accurate Statements
Label excerpts provided include: COSENTYX contraindicated in patients with previous serious hypersensitivity to secukinumab/excipients; serious hypersensitivity reactions (including anaphylaxis/angioedema/urticaria) reported; and warnings regarding infections/TB evaluation/IBD exacerbations, eczematous eruptions, latex, and live vaccines.
Contraindications (4); Warnings/Precautions (5.1-5.7); Adverse Reactions (6.1-6.2); Immunizations (5.7); Clinical Pharmacology (12.2).
Unsupported Statements
“No specific user claim text was provided. The assessment is based on the general label content you supplied indicating that these safety/precaution statements are supported by the referenced FDA labeling sections.”
The user did provide specific claims (Cosentyx/MMR vaccine efficacy and study descriptions), but the response did not perform line-by-line verification of those claims. It instead evaluates an unrelated generalized safety/risks topics list.
“The provided label-support mapping indicates the safety/risks topics are appropriately covered and aligned with the referenced FDA labeling sections. No contradictions, omissions, or off-label safety inferences are indicated.”
The response never substantiates alignment for the specific MMR/vaccine-efficacy assertions (e.g., pharmacokinetics with MMR, phase IV 2020 study findings, EMA/FDA statement about MMR efficacy risk). The supplied label excerpts do not contain those asserted specifics.
“COSENTYX may alter a patient's immune response to live vaccines; Avoid use of live vaccines in patients treated with COSENTYX.” (as part of generalized mapping)
While this is supported by the label excerpt, it is not tied to the specific MMR-focused claims and therefore does not establish support for the user’s MMR-efficacy interference claims.
Items claiming evidence for “pharmacokinetic study in healthy subjects… does not significantly affect pharmacokinetics of the MMR vaccine” and “pharmacodynamic study… no detrimental effects on vaccine efficacy.”
These specific study types/outcomes for MMR are not supported by the provided label excerpts.
“Phase IV study in 2020 found no statistically significant difference… adverse events/immune-related adverse events between COSENTYX and placebo.”
No such phase IV 2020 study details are contained in the provided label excerpts; the response offers no label citation for these assertions.
“No established risk… reducing efficacy of the MMR vaccine (according to EMA and the US FDA).”
The provided label excerpts do not state an absence of established risk for MMR vaccine efficacy; therefore this assertion is unsupported by the supplied label text.
“Clinical experience… has not revealed any widespread concerns regarding vaccine efficacy.”
Not supported by the provided label excerpts.
“Guidelines recommend… follow standard vaccination recommendations, including the MMR vaccine.”
The provided label excerpts state to consider completion of age-appropriate immunizations and avoid live vaccines; they do not endorse standard vaccination recommendations specifically including MMR for patients on COSENTYX.
Contradictions
Low
AI Statement
“Guidelines recommend that patients receiving Cosentyx should follow standard vaccination recommendations, including the MMR vaccine.”
Label Reference
Warnings and Precautions 5.7 (Immunizations): “COSENTYX may alter a patient's immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.”
Important Omissions
Line-by-line assessment of each user-provided MMR-specific claim (MMR protection alteration, phase IV 2020 outcomes, vaccine efficacy interference concerns, PK/PD studies with MMR, EMA/FDA statements on MMR efficacy risk, and guideline inclusion of MMR) against the provided FDA label excerpts.
Importance:
High
Direct citation from the provided label excerpts (sections 4, 5.1-5.7, 6.1-6.2, 12.2) to support or refute the specific MMR vaccine efficacy/interference assertions.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The response includes unsupported and partially label-inconsistent claims about MMR/vaccine efficacy and including MMR vaccination, while the label excerpt emphasizes avoiding live vaccines during COSENTYX treatment. This could lead to unsafe vaccination assumptions if acted upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
The audit did not evaluate the provided MMR-specific claims against the supplied FDA label excerpts and instead made generalized/unsupported study and regulator statements not present in the label text provided.
Suggested Improvement
Evaluate each MMR-specific claim individually using only the provided label excerpts; avoid asserting PK/PD/phase IV 2020 study results or EMA/FDA statements unless directly supported by cited label text. For immunizations, align statements strictly with 5.7 (avoid live vaccines) rather than recommending MMR inclusion without label support.